登录

Jiangsu ASK Pharm Plans to Inject ¥36 million into Guike Pharmaceutical

作者: Mailman 2020-02-18 17:55
奥赛康药业
http://www.ask-pharm.com
企业数据由 动脉橙 提供支持
新型药物研发商 | IPO | 运营中
中国-北京
2015-05-15
融资金额:RMB¥1.898亿
查看

According to the announcement of Aosaikang Pharm ("ASK Pharm"), Jiangsu Aosaikang Pharmaceutical Co., Ltd. ("Jiangsu ASK Pharm"), a subsidiary of ASK Pharm, Lianyungang Guike Pharmaceutical Co., Ltd. ("Guike Pharmaceutical") and the shareholders of Guike Pharmaceutical--Kong Yin and Suzhou Lanxite Biotechnology Co., LTD. have jointly signed an investment agreement. Jiangsu ASK Pharm plans to inject money into Guike Pharmaceutical with its own capital of 36 million yuan. After the capital increase, Jiangsu ASK Pharm will obtain 33.96% equity of Guike Pharmaceutical.


Guike Pharmaceutical is a high-tech integrated pharmaceutical enterprise focusing on research, development, production, and sales of pharmaceutical raw materials. The capital increase will be used for the construction of the pharmaceutical raw materials workshop. ASK Pharm and its subsidiaries will fully participate in the process design, equipment selection and other work.


The workshop will be used to support the R&D and production of ASK Pharm and its subsidiaries, speed up the product transformation, and enhance competitiveness.


Founded in January 2003, Jiangsu ASK Pharm is a research-based pharmaceutical enterprise that integrates and streamlines innovative research and development with the manufacture, marketing promotion and sales of proprietary pharmaceuticals, fine chemicals, and health-care products.


At present, Jiangsu ASK Pharm has established a systematical administration and operation structure, with a comprehensive management system, superior R&D facility, state-of-the-art manufacturing capacity, sustainable product quality assurance, professional sales network, and after-marketing drug use monitoring and surveillance.


Jiangsu ASK Pharm specializes in proton pump inhibitor (PPI) products and oncology medicines. Its specialization and expertise in lyophilized parenteral products are unique and top-notch in China. Its GMP facilities have consecutively passed both national and provincial certifications for 11 times.

文章标签 医药投融资
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

瑞初医药天使轮融资,动平衡资本领投,有力推进衰老及衰老相关疾病创新药研发

【首发】Redbud Medicine完成千万美元A轮融资,聚明创投与德联资本联合领投,浩悦资本担任独家财务顾问

【首发】恩凯赛药获逾亿元A轮融资,成NK细胞免疫治疗全球赛道强劲黑马

【首发】迈邦生物完成亿元人民币B轮融资,持续推进生物技术上游核心原材料国产化

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

浪潮健康宣布完成A轮融资,区域医疗健康大数据平台在抗疫战中价值凸显

2020-02-18
下一篇

Anngeen Technologies Snags¥100M in Series B Round

2020-02-18